AD/PD 2021 | MCLENA-1: lenalidomide in mild cognitive impairment due to Alzheimer’s disease

Marwan Sabbagh, MD, Lou Ruvo Center for Brain Health, Las Vegas, NV, outlines the rationale and design for the Phase II, double-blind, randomized, placebo-controlled clinical trial (NCT04032626) assessing the safety, tolerability, and efficacy of lenalidomide in mild cognitive impairment due to Alzheimer’s disease. The study, currently enrolling patients, aims to test the hypothesis that lenalidomide, a pleiotropic immunomodulatory agent, reduces inflammatory and Alzheimer’s disease-associated pathological biomarkers and improves cognition. This interview took place during the AD/PD™ 2021 conference.